Indian experience of Afatinib for EGFR mutation-positive advanced lung adenocarcinoma a real-world retrospective study
Currently, there are multiple first-line strategies to manage advanced NSCLC in India including EGFR TKIs. To the best of our knowledge, this is the first real-world study published from India which looks into the efficacy of Afatinib in advanced NSCLC. Afatinib showed a manageable safety profile and comparable efficacy in real-world practice compared with those described in previous studies.
Authors
- Praveen Jain (ORCID: https://orcid.org/0000-0003-3917-4115)
- Satya Narayan (ORCID: https://orcid.org/0000-0001-7080-8900)
- Ullas Batra
- Mansi Sharma (ORCID: https://orcid.org/0000-0002-4026-5498)
- Shrinidhi Nathany (ORCID: https://orcid.org/0000-0001-6006-6309)
- Arpit Jain
- Satyajeet Soni (ORCID: https://orcid.org/0000-0003-2564-2619)
Institutions
- Rajiv Gandhi Cancer Institute and Research Centre (IN)
Publication Details
- Journal
- Indian Journal of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.4103/ijc.ijc_893_20
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00